We summarise key insights from the pharmaceutical, pricing and market access sector:
- NICE has recommended Yescarta as the first CAR T-cell therapy for the treatment of lymphoma
- IQWiG criticises the orphan drug rules, following one which voluntarily underwent the standard AMNOG process.
- Price cuts for generics could exacerbate ongoing problem with drug shortages in France
Our Latest Articles: